Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Andrea Holíčková"'
Autor:
Patrik Palacka, Andrea Holíčková, Jan Roška, Peter Makovický, Miroslava Vallová, Csaba Biró, Eveline Órásová, Jana Obertová, Jozef Mardiak, Thomas A. Ward, Karol Kajo, Miroslav Chovanec
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background Cisplatin (CDDP) remains a key agent in the treatment of muscle-infiltrating bladder carcinoma (MIBC). However, a proportion of MIBC patients do not respond to chemotherapy, which may be caused by the increased repair of CDDP-indu
Externí odkaz:
https://doaj.org/article/761780bca58d45ffaf4f2ed1c5328ebb
Autor:
Danica Ivovič, Zuzana Šestáková, Jan Roška, Katarína Kálavská, Lenka Hurbanová, Andrea Holíčková, Božena Smolková, Pavlína Kabelíková, Věra Novotná, Michal Chovanec, Patrik Palacka, Michal Mego, Dana Jurkovičová, Miroslav Chovanec
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundGerm cell tumors (GCTs) represent the most frequent solid malignancy in young men. This malignancy is highly curable by cisplatin (CDDP)-based chemotherapy. However, there is a proportion of patients having a poor prognosis due to refractor
Externí odkaz:
https://doaj.org/article/7ca865402d77409db04d838cc3902f32
Autor:
Andrea Holíčková, Jan Roška, Eveline Órásová, Vladimíra Bruderová, Patrik Palacka, Dana Jurkovičová, Miroslav Chovanec
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 20, p 12488 (2022)
Cisplatin (CDDP)-based chemotherapy is the standard of care in patients with muscle-invasive bladder cancer. However, in a large number of cases, the disease becomes resistant or does not respond to CDDP, and thus progresses and disseminates. In such
Externí odkaz:
https://doaj.org/article/29bc1fdb3f4a482890ff8a984f6e732f